BioXCell熱銷產(chǎn)品--RecombiMAb anti-mouse PD-1 (CD279)
?
產(chǎn)品描述:
29F.1A12?-CP004單克隆抗體是原始29F.1A12?克隆號的重組嵌合型抗體??勺兘Y(jié)構(gòu)域序列與原始29F.1A12?克隆號相同,但是恒定區(qū)序列已經(jīng)從大鼠IgG2a變?yōu)樾∈驣gG1。29F.1A12?-CP004抗體像原始大鼠IgG2a抗體一樣無Fc突變。
29F.1A12?-CP004單克隆抗體與小鼠PD-1(程序性死亡-1蛋白,也稱為CD279)反應。PD-1是一種50-55 kDa的細胞表面受體,由Pdcd1基因編碼,屬于免疫球蛋白超家族的CD28家族。PD-1在CD4和CD8胸腺細胞以及活化的T和B淋巴細胞和骨髓細胞上瞬時表達。成功清除抗原后,PD-1表達下降。此外,Pdcd1 mRNA在前B細胞階段發(fā)育中的B淋巴細胞中表達。PD-1的結(jié)構(gòu)包括一個ITIM(免疫受體酪氨酸抑制基序),表明PD-1負調(diào)節(jié)TCR信號。PD-1通過結(jié)合它的兩個配體PD-L1和PD-L2發(fā)出信號,這兩個配體都是B7家族的成員。配體結(jié)合后,PD-1信號抑制T細胞活化,導致增殖、細胞因子產(chǎn)生和T細胞死亡減少。此外,已知PD-1在小鼠的外周耐受性和預防自身免疫性疾病中起關(guān)鍵作用,因為PD-1敲除動物表現(xiàn)出擴張性心肌病、脾腫大和外周耐受性喪失。誘導的PD-L1表達常見于許多腫瘤,包括鱗狀細胞癌、結(jié)腸腺癌和乳腺腺癌。PD-L1過度表達導致腫瘤細胞對CD8 T細胞介導的裂解的抗性增加。在黑色素瘤的小鼠模型中,通過用阻斷PD-L1和它的受體PD-1之間的相互作用,腫瘤生長可以暫時被抑制。目前PD-1是癌癥免疫療法的熱門靶點之一。
?
產(chǎn)品詳情:
產(chǎn)品名稱 | RecombiMAb anti-mouse PD-1 (CD279) |
產(chǎn)品貨號 | CP004 |
產(chǎn)品規(guī)格 | 1mg |
反應種屬 | Mouse |
克隆號 | 29F.1A12?-CP004 |
同種型 | Mouse IgG1(switched from rat IgG2a) |
免疫原 | Recombinant PD-1-Ig fusion protein |
實驗應用 | in vivo blocking of PD-1/PD-L signaling* in vitro PD-1 neutralization* Immunohistochemistry (frozen)* Immunofluorescence* Western blot* Flow cytometry* *Reported for the original rat IgG2a 29F.1A12 antibody |
產(chǎn)品形式 | PBS, pH 7.0,Contains no stabilizers or preservatives |
純度 | >95%, Determined by SDS-PAGE |
聚合 | <5%, Determined by SEC |
無菌處理 | 0.2 μm filtration |
純化方式 | Protein G |
分子量 | 150 kDa |
小鼠病原檢測 | Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
保存條件 | 抗體原液保存在4°C,不能冷凍保存。 |
推薦同型對照 | InVivoPlus mouse IgG1 isotype control, unknown specificity(貨號BP0083) |
推薦抗體稀釋液 | InVivoPure pH 7.0 Dilution Buffer(貨號IP0070) |
?
該產(chǎn)品自上市已被多篇SCI文獻引用,品質(zhì)有保證,以下是部分已發(fā)表的文獻引用:
應用 | 文章 |
體內(nèi)PD-1/PD-L信號阻斷 (in vivo blocking of PD-1/ PD-L signaling) | 1.?Wang, W., et al. (2018). 'RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune? Tolerance in Pancreatic Cancer' Cancer Cell 34(5): 757-774 e757.
2.?Gordon, S. R., et al. (2017). 'PD-1 expression by tumour-associated macrophages? inhibits phagocytosis and tumour immunity' Nature 545(7655): 495-499.
3.?Koyama, S., et al. (2016). 'STK11/LKB1 Deficiency Promotes Neutrophil Recruitment? and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor? Microenvironment' Cancer Res 76(5): 999-1008. |
體內(nèi)PD-1/PD-L信號阻斷, 流式細胞術(shù) (in vivo blocking of PD-1/ PD-L signaling,?Flow Cytometry) | 1.Koyama, S., et al. (2016). 'Adaptive resistance to therapeutic PD-1 blockade is? associated with upregulation of alternative immune checkpoints' Nat Commun 7: 10501. |
體外PD-1中和 (in vitro PD-1 neutralization) | 1.Park, S. J., et al. (2014). 'Negative role of inducible PD-1 on survival of activated? dendritic cells' J Leukoc Biol 95(4): 621-629. |
體內(nèi)PD-1/PD-L信號阻斷, 體外PD-1中和(in vivo blocking? of PD-1/PD-L signaling,?in vitro? PD-1?neutralization) | 1.Duraiswamy, J., et al. (2013). 'Dual blockade of PD-1 and CTLA-4 combined with? tumor vaccine effectively restores T-cell rejection function in tumors' Cancer Res 73 (12): 3591-3603. |
流式細胞術(shù) (Flow Cytometry) | 1.Good-Jacobson, K. L., et al. (2012). 'CD80 expression on B cells regulates murine? T follicular helper development, germinal center B cell survival, and plasma cell? generation'?J Immunol 188(9): 4217-4225. |
?
更多產(chǎn)品詳情請咨詢?BioXCell?中國授權(quán)代理——欣博盛生物
全國服務(wù)熱線: 4006-800-892 ? ? ??郵箱: market@neobioscience.com?
深圳: 0755-26755892 ? ? ? ??北京: 010-88594029 ???????????
廣州:020-87615159???????????上海: 021-34613729
代理品牌網(wǎng)站: m.smblzp.com?
自主品牌網(wǎng)站: www.neobioscience.net?